Islem Ouanes
University of Monastir
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Islem Ouanes.
American Journal of Respiratory and Critical Care Medicine | 2015
François Philippart; Stéphane Gaudry; Laurent Quinquis; Nicolas Lau; Islem Ouanes; Samia Touati; Jean Claude Nguyen; Catherine Branger; Frédéric Faibis; Maha Mastouri; Xavier Forceville; Fekri Abroug; Jean Damien Ricard; Sophie Grabar; Benoit Misset
RATIONALE The occurrence of ventilator-associated pneumonia (VAP) is linked to the aspiration of contaminated pharyngeal secretions around the endotracheal tube. Tubes with cuffs made of polyurethane rather than polyvinyl chloride or with a conical rather than a cylindrical shape increase tracheal sealing. OBJECTIVES To test whether using polyurethane and/or conical cuffs reduces tracheal colonization and VAP in patients with acute respiratory failure. METHODS We conducted a multicenter, prospective, open-label, randomized study in four parallel groups in four intensive care units between 2010 and 2012. A cohort of 621 patients with expected ventilation longer than 2 days was included at intubation with a cuff composed of cylindrical polyvinyl chloride (n = 148), cylindrical polyurethane (n = 143), conical polyvinyl chloride (n = 150), or conical polyurethane (n = 162). We used Kaplan-Meier estimates and log-rank tests to compare times to events. MEASUREMENTS AND MAIN RESULTS After excluding 17 patients who secondarily refused participation or had met an exclusion criterion, 604 were included in the intention-to-treat analysis. Cumulative tracheal colonization greater than 10(3) cfu/ml at Day 2 was as follows (median [interquartile range]): cylindrical polyvinyl chloride, 0.66 (0.58-0.74); cylindrical polyurethane, 0.61 (0.53-0.70); conical polyvinyl chloride, 0.67 (0.60-0.76); and conical polyurethane, 0.62 (0.55-0.70) (P = 0.55). VAP developed in 77 patients (14.4%), and postextubational stridor developed in 28 patients (6.4%) (P = 0.20 and 0.28 between groups, respectively). CONCLUSIONS Among patients requiring mechanical ventilation, polyurethane and/or conically shaped cuffs were not superior to conventional cuffs in preventing tracheal colonization and VAP. Clinical trial registered with clinicaltrials.gov (NCT01114022).
European Respiratory Journal | 2014
Fekri Abroug; Lamia Ouanes-Besbes; Mohamed Fkih-Hassen; Islem Ouanes; S. Ayed; Fahmi Dachraoui; Laurent Brochard; Souheil Elatrous
Recommendation of the use of systemic steroids in chronic obstructive disease (COPD) exacerbation rely on trials that excluded patients requiring ventilatory support. In an open-label, randomised evaluation of oral prednisone administration, 217 patients with acute COPD exacerbation requiring ventilatory support were randomised (with stratification on the type of ventilation) to usual care (n=106) or to receive a daily dose of prednisone (1 mg·kg−1) for up to 10 days (n=111). There was no difference regarding the primary end-point, intensive care unit mortality, which was 17 (15.3%) deaths versus 15 (14%) deaths in the steroid-treated and control groups, respectively (relative risk 1.08, 95% CI 0.6–2.05). Analysis according to ventilation modalities showed similar mortality rates. Noninvasive ventilation failed in 15.7% and 12.7% (relative risk 1.25, 95% CI 0.56–2.8; p=0.59), respectively. Both study groups had similar median mechanical ventilation duration and intensive care unit length of stay, which were 6 (interquartile range 6–12) days versus 6 (3.8–12) days and 9 (6–14) days versus 8 (6–14) days, respectively. Hyperglycaemic episodes requiring initiation or alteration of current insulin doses occurred in 55 (49.5%) patients versus 35 (33%) patients in the prednisone and control groups, respectively (relative risk 1.5, 95% CI 1.08–2.08; p=0.015). Prednisone did not improve intensive care unit mortality or patient-centred outcomes in the selected subgroup of COPD patients with severe exacerbation but significantly increased the risk of hyperglycaemia. In COPD exacerbation needing ventilatory support, prednisone has no impact on ICU mortality or related patient outcome http://ow.ly/qxGq0
Emerging Infectious Diseases | 2014
Fekri Abroug; Amine Slim; Lamia Ouanes-Besbes; Mohamed-Ali Hadj Kacem; Fahmi Dachraoui; Islem Ouanes; Xiaoyan Lu; Ying Tao; Clinton R. Paden; Hayat Caidi; Congrong Miao; Mohammed Mohammed Al-Hajri; Mokhtar Zorraga; Wissem Ghaouar; Afif BenSalah; Susan I. Gerber
In 2013 in Tunisia, 3 persons in 1 family were infected with Middle East respiratory syndrome coronavirus (MERS-CoV). The index case-patient’s respiratory tract samples were negative for MERS-CoV by reverse transcription PCR, but diagnosis was retrospectively confirmed by PCR of serum. Sequences clustered with those from Saudi Arabia and United Arab Emirates.
Emergency Medicine Journal | 2011
Fekri Abroug; Lamia Ouanes-Besbes; Islem Ouanes; Fahmi Dachraoui; Mohamed Fkih Hassen; Habib Haguiga; Souheil Elatrous; Christian Brun-Buisson
Background Despite conflicting evidence, specific serotherapy is recommended for scorpion envenomation. Methods A meta-analysis of prospective or observational controlled studies, comparing intravenous scorpion antivenin (SAV) with control, was performed. Binary outcomes are reported as risk difference for clinical improvement and mortality rates. Analysis was performed both for the whole number of included studies and for two subgroups (set up according to the geographic origin of scorpions). Results Nine studies (four randomised controlled trials (RCTs), five observational) enrolling 687 patients were identified. Six dealt with Old World scorpions and three originated from Arizona. Overall, the rate of clinical improvement was similar in SAV treated and untreated patients (risk difference=0.22, 95% CI −0.35 to 0.79; p=0.45 for effect). Subgroup analysis showed favourable effects of SAV in the Arizona scorpion envenomation (risk difference=0.53; 95% CI 0.16 to 0.91; p<0.001), and non-significant unfavourable effects in Old World scorpion envenomation (risk difference=−0.05; 95% CI −0.28 to 0.18; p=0.65; p=0.003 for z-value, indicating a true heterogeneity of treatment effects). In Old World scorpion envenomation, there was no statistical difference in the risk of death in SAV treated and untreated scorpion envenomated patients (risk difference=0.007, 95% CI −0.02 to 0.03; p=0.6 for effect). Overall, administration of scorpion antivenin was associated with a reduction by 13 h in the mean time of symptom resolution (95% CI −17 to −9; p<0.0001). Serious adverse events were reported at a rate of 1–2% while minor adverse events occurred in up to 40% of patients. Conclusions SAV should not be administered in Old World scorpion envenomation until its efficacy is established by an appropriately designed RCT. In the Arizona scorpion sting, SAV hastens the recovery process.
Clinical Toxicology | 2015
Fekri Abroug; Elatrous Souheil; Islem Ouanes; Fahmi Dachraoui; Mohamed Fekih-Hassen; Lamia Besbes
Abstract Context. Scorpion envenomation is a threat to more than 2 billion people worldwide with an annual sting number exceeding one million. Acute heart failure presenting as cardiogenic shock or pulmonary edema, or both is the most severe presentation of scorpion envenomation accounting for 0.27% lethality rate. Objective. The purpose of this review is to characterize the scorpion-related cardiomyopathy, clarify its pathophysiological mechanisms, and describe potentially useful treatments in this particular context. Methods. We searched major databases on observational or interventional studies (whether clinical or experimental) on the cardiorespiratory consequences of scorpion envenomation and their treatment. No limit of age or language was imposed. A critical appraisal of the literature was conducted in order to provide a pathophysiological scheme that reconciles reported patterns of cardiovascular toxicity and hypotheses and assumptions made so far. Results. Early cardiovascular dysfunction is related to the so-called “vascular phase” of scorpion envenomation, which is related to a profound catecholamine-related vasoconstriction leading to a sharp increase in left ventricular (LV) afterload, thereby impeding LV emptying, and increasing LV filling pressure. Following this vascular phase, a myocardial phase occurs, characterized by a striking alteration in LV contractility (myocardial stunning), low cardiac output, and hypotensive state. The right ventricle involvement is symmetric to that of LV with a profound and reversible alteration in right ventricular performance. This phase is unique in that it is reversible spontaneously or under inotropic treatment. Scorpion myocardiopathy combines the features of takotsubo myocardiopathy (or stress myocardiopathy) which is linked to a massive release in catecholamines leading to myocardial ischemia through coronary vasomotor abnormalities (epicardial coronary spasm and/or increase in coronary microvascular resistance). Treatment of pulmonary edema due to scorpion envenomation follows the same principles as those applied for the treatment of cardiogenic pulmonary edema in general: this begins with oxygen supplementation targeting an oxygen saturation of 92% or more, by oxygen mask, continuous positive airway pressure, noninvasive ventilation, or conventional mechanical ventilation. Dobutamine effectively improves hemodynamic parameters and may reduce mortality in severe scorpion envenomation. Conclusion. Scorpion cardiomyopathy is characterized by a marked and reversible alteration in biventricular performance. Supportive treatment relying on ventilatory support and dobutamine infusion is a bridge toward recovery in the majority of patients.
Journal of Critical Care | 2011
Lamia Ouanes-Besbes; Islem Ouanes; Fahmi Dachraoui; Saoussen Dimassi; Alexandre Mebazaa; Fekri Abroug
PURPOSE To compare the short-term hemodynamic effects of levosimendan and dobutamine in chronic obstructive pulmonary disease (COPD) patients experiencing weaning difficulties in relation with increased left ventricular filling pressure. MATERIALS AND METHODS This prospective, sequential, pilot study included 10 COPD patients experiencing weaning difficulties in relation with increased left ventricular filling pressure ascertained by an increase >10 mm Hg of pulmonary artery occlusion pressure (PAOP) at the shift from mechanical to spontaneous breathing (SB). Patients received 1 h infusion of 7 μg/kg per minute of dobutamine, followed by 24-hour infusion of 0.2 μg/kg per minute levosimendan. Hemodynamic variables were measured under MV and 15 to 30 minutes after SB at baseline, at the end of dobutamine infusion, at a washout period, and after levosimendan infusion. RESULTS At baseline, the shift from mechanical ventilation to spontaneous ventilation was associated with a significant increase in PAOP from a median of 15 (interquartile range [IQR], 6) to 29 (9) mm Hg. Both drugs reduced significantly the level of PAOP increase at SB, but levosimendan had a greater effect than dobutamine [median PAOP increase (IQR): 5 (2) vs 9 (4) mm Hg, respectively; P < .01]. CONCLUSIONS Both drugs reduced the magnitude of PAOP increase at SB in difficult-to-wean COPD patients. PAOP increase was reduced to a greater extent by levosimendan.
Respirology | 2012
Islem Ouanes; Faten Jalloul; S. Ayed; Fahmi Dachraoui; Lamia Ouanes-Besbes; Mohamed Fekih Hassen; Souheil Elatrous; Fekri Abroug
Background and objective: The aim of this study was to assess the performance of N‐terminal proB‐type natriuretic peptide (NT‐proBNP) levels for the diagnosis of left ventricular dysfunction in patients with severe acute exacerbations of chronic obstructive pulmonary disease (COPD) and renal dysfunction.
Annals of Intensive Care | 2014
Fekri Abroug; Islem Ouanes; Sarra Abroug; Fahmi Dachraoui; Saoussen Ben Abdallah; Zeineb Hammouda; Lamia Ouanes-Besbes
Guidelines on systemic corticosteroids in chronic obstructive pulmonary disease (COPD) exacerbation rely on studies that excluded patients requiring ventilatory support. Recent publication of studies including ICU patients allows estimation of the level of evidence overall and in patients admitted to the ICU. We included RCTs evaluating the efficacy and safety of systemic corticosteroids in COPD exacerbation, compared to placebo or standard treatment. The effect size on treatment success was computed by a random effects model overall and in subgroups of non-ICU and ICU patients. Effects on mortality and on the rate of adverse effects of corticosteroids were also computed. Twelve RCTs (including 1,331 patients) were included. Pooled analysis showed a statistically significant increase in the treatment success rate when using systemic corticosteroids: odds ratio (OR) = 1.72, 95% confidence interval (CI) = 1.15 to 2.57; p = 0.01. Subgroup analysis showed different patterns of effect in ICU and non-ICU subpopulations: a non-significant difference of effect in the subgroup of ICU patients (OR = 1.34, 95% CI = 0.61 to 2.95; p = 0.46), whereas in the non-ICU patients, the effect was significant (OR = 1.87, 95% CI = 1.18 to 2.99; p = 0.01; p for interaction = 0.72). Among ICU patients, there was no difference in the success whether patients were ventilated with tracheal intubation (OR = 1.85, 95% CI = 0.14 to 23.34; p = 0.63) or with non-invasive ventilation (OR = 4.88, 95% CI = 0.31 to 75.81; p = 0.25). Overall, there was no difference in the mortality rate between the steroid-treated group and controls: OR = 1.07, 95% CI = 0.67 to 1.71; p = 0.77. The rate of adverse events increased significantly with corticosteroid administration (OR = 2.36, 95% CI = 1.67 to 3.33; p < 0.0001). In particular, treatment with systemic corticosteroids significantly increased the risk of hyperglycemic episodes requiring initiation or alteration of insulin therapy (OR = 2.96, 95% CI = 1.69 to 5; p < 0.0001). We found corticosteroids to be beneficial in the whole population (non-critically ill and critically ill patients) in terms of treatment success rate. However, subgroup analysis showed that this effect of corticosteroids was only observed in non-critically ill patients whereas critically ill patients derived no benefit from systemic corticosteroids regardless of the chosen ventilatory mode (invasive or non-invasive ventilation). Further analyses showed no effect on mortality of corticosteroids, but higher side effects, such as hyperglycemic episodes requiring the initiation or alteration of insulin therapy.
Toxicon | 2015
Souheil Elatrous; Lamia Ouanes-Besbes; Habiba Ben Sik-Ali; Zineb Hamouda; Saoussen BenAbdallah; Nejla Tilouche; Faten Jalloul; Mohamed Fkih-Hassen; Fahmi Dachraoui; Islem Ouanes; Fekri Abroug
To evaluate the dose-effects of Androctonus australis hector (Aah) venom injected subcutaneously on hemodynamics and neurohormonal secretions, 10 anesthetized and ventilated mongrel dogs, were split in two groups (n = 5/group). Subcutaneous injection was done with either 0.2 mg/kg or 0.125 mg/kg of the purified G50 scorpion toxic fraction. Hemodynamic parameters using right heart catheter were recorded and plasma concentrations of catecholamine, troponin, and serum toxic fraction were measured sequentially from baseline to 120 min. We identified the dose of toxic fraction evoking characteristic hemodynamic perturbation of severe envenomation, the time-lapse to envenomation, and the associated plasma level. The injection of 0.125 mg/kg toxic fraction was not associated with significant variations in hemodynamic parameters, whereas the 0.2 mg/kg dose caused envenomation characterized by significant increase in plasma catecholamines, increased pulmonary artery occluded pressure, mean arterial pressure, and systemic vascular resistance (p < 0.05), in association with sustained decline in cardiac output (p < 0.001). Envenomation occurred by the 30th minute, and the corresponding concentration of toxic fraction was 1.14 ng/ml. The current experiment allowed the identification of the sub-lethal dose (0.2 mg/kg) of the toxic fraction of Aah administered by the subcutaneous route. Two parameters with potential clinical relevance were also uncovered: the time-lapse to envenomation and the corresponding concentration of toxic fraction.
Canadian Journal of Anaesthesia-journal Canadien D Anesthesie | 2009
Islem Ouanes; Lamia Ouanes-Besbes; Fekri Abroug
To the Editor, Succinylcholine, a hypnotic and depolarizing neuromuscular blocking agent, is a drug recommended for rapid sequence intubation. Organophosphates and carbamate insecticides, which may be used in suicide attempts, inhibit both plasma cholinesterase and acetylcholinesterase, and they may also extend the duration of action of succinylcholine and prolong neuromuscular blockade. We report a case of life-threatening trismus involving the delayed interaction between succinylcholine and carbamate poisoning. An 18-year-old woman was admitted to the intensive care unit following a suicide attempt with a carbamate insecticide (methomyl). She had the following symptoms of severe carbamate poisoning: coma, fasciculations, salivation, lacrimation, myosis, bronchorrhea, and difficult breathing. Her arterial blood pressure was normal and her heart rate was 56 beats min. Tracheal intubation was performed after propofol administration, and mechanical ventilation was instituted. Plasma cholinesterase activity was low, 430 U L (normal: 4000–6000 U L). Activated charcoal was given and intravenous atropine was administered. After 3 days, the patient experienced spontaneous gastric perforation and peritonitis for which surgical peritoneal irrigation was performed and intravenous antibiotics (amoxicillin-clavulanate and gentamicin) were administered. Her trachea was extubated by day 10 when both carbamate poisoning and peritonitis had clinically resolved. Her respiratory and hemodynamic status was stable, her body temperature was normal, and she was alert. Blood tests showed a white blood cell count of 7200 mm, hemoglobin 120 g L, potassium 3.9 mmol L, and plasma cholinesterase activity 1500 U L. Less than 30 min after tracheal extubation, the patient’s respiratory status worsened because of major bronchorrhea and inefficient cough. Tracheal intubation was then attempted after the simultaneous administration of propofol 150 mg and succinylcholine 60 mg intravenously. Within seconds, a strong trismus, or spasm of the masseter muscles, was observed, preventing mouth opening and orotracheal intubation. Despite administration of oxygen via bag and a face mask, sustained oxygen desaturation occurred throughout the 20-min intubation procedure (lowest recorded value, 84%). A fibroscopy-guided nasotracheal intubation was therefore attempted, during which cardiac arrest occurred prompting immediate cardiopulmonary resuscitation. Oxygen delivery continued via bag and face mask and epinephrine (total dose, 6 mg) was administered. Fibreoptic nasotracheal intubation was ultimately successful by the 20th minute, and return of spontaneous circulation was achieved by the 25th minute. Mechanical ventilation was instituted, and sedation was provided with midazolam and remifentanil. Trismus progressively subsided between 4 and 8 h following its onset. Despite recovery of normal blood pressure and oxygenation, the electroencephalogram performed one day following the hypoxic episode indicated a pattern compatible with brain death. The patient died 3 days later. This report shows that administration of succinylcholine might be associated with severe trismus even late in the setting of carbamate poisoning; therefore, administering succinylcholine in this setting should be considered contraindicated. Using the Naranjo adverse drug reaction probability scale, we calculated a score of 6 (a score of 5–8 out of 13 indicates a probable relation between the I. Ouanes, MD L. Ouanes-Besbes, MD F. Abroug, MD (&) CHU F. Bourguiba, Monastir, Tunisia e-mail: [email protected]